Studies published in “Oncotarget” demonstrate that targeting MUC1-C with GO-203 is highly synergistic with decitabine against AML cells

​These findings provided the basis for their translation to a Phase Ib/IIa trial of combining GO-203 with decitabine for the treatment patients with relapsed/refractory AML.  

DETAILS